Levi & Korsinsky Reminds Maravai LifeSciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 5, 2025 – MRVI

Core Viewpoint - A class action securities lawsuit has been filed against Maravai LifeSciences Holdings, Inc. alleging securities fraud that affected investors between August 7, 2024, and February 24, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that Maravai LifeSciences lacked adequate internal controls over financial reporting related to revenue recognition [2]. - It is alleged that the Company inaccurately recognized revenue on certain transactions during fiscal 2024 [2]. - The complaint also states that the goodwill of the Company was overstated, leading to materially misleading positive statements about its business and operations [2]. Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until May 5, 2025, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].